A healthcare device maker looks like a steady long-term add for someone trying to spread risk beyond big drug companies, helped by a recent buyout that broadens its brain-related tech offerings. The appeal is slow-and-steady growth and a long history of raising its payout, though the outlook isn’t flashy and some experts sound cautious.Read more
Medtronic looks like a steady medical-device business that may be overlooked, even as new products in robot-assisted surgery and diabetes care start to gain traction. The big question is whether it can turn its innovation pipeline into faster growth while navigating tough regulators, fierce rivals, and pricing pressure from hospitals.Read more
Medtronic sells everyday medical technology that hospitals rely on, and it could get a lift as new tools in robotic surgery and diabetes care gain traction while demand rises with an aging population. The key question is whether it can out-execute bigger rivals and avoid delays from regulators, product issues, and supply chain snags.Read more
Medtronic’s next chapter leans on a few fast-growing therapies and tools, especially new heart rhythm treatments and a push into surgical robotics, to lift growth as more hospitals and doctors adopt them. The key question is whether this momentum holds up as costs and weaker product lines tug the other way.Read more
Medtronic is leaning into fast-growing areas like heart rhythm care, less invasive blood pressure treatments, and robot-assisted surgery, which could gradually lift demand for its devices and services. But many of these newer platforms are still early, so the long-term outlook depends on whether hospitals adopt them widely and how well Medtronic’s deal-making pays off.Read more
Medtronic is leaning into robotic surgery and connected health tools as hospitals look for less invasive care and better ways to manage chronic disease. A planned separation of its diabetes unit could sharpen its focus, but weak spots in parts of the business and the risk of bumpy product rollouts may hold results back.Read more
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients in the United States, Ireland, and internationally. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves, and percutaneous coronary intervention products, percutaneous angioplasty balloons, and other products. The Neuroscience Portfolio segment offers medical devices and implants, biologic solutions, spinal cord stimulation and brain modulation systems, implantable drug infusion systems, and interventional products, as well as nerve ablation system under the Accurian name. The segment offers its products for spinal surgeons, neurosurgeons, neurologists, pain management specialists, anesthesiologists, orthopedic surgeons, urologists, urogynecologists, and interventional radiologists, as well as ear, nose, and throat specialists, and energy surgical instruments. The Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure and electrosurgery products, AI-powered surgical video and analytics platform, robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology products, gastrointestinal and hepatologic diagnostics and therapies, and therapies to treat diseases and conditions, and patient monitoring and airway management products. The Diabetes Operating Unit segment provides insulin pumps and consumables, continuous glucose monitoring systems and sensors, and InPen, a smart insulin pen. Medtronic plc was founded in 1949 and is headquartered in Galway, Ireland.
